Cargando…
Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data
BACKGROUND: Esophageal adenocarcinoma has a very poor prognosis unless detected early. The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a precursor of esophageal adenocarcinoma. Randomised controlled trial data from the BEST3 trial has shown that an offer of Cyt...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225801/ https://www.ncbi.nlm.nih.gov/pubmed/34195582 http://dx.doi.org/10.1016/j.eclinm.2021.100969 |
_version_ | 1783712148705247232 |
---|---|
author | Swart, Nicholas Maroni, Roberta Muldrew, Beth Sasieni, Peter Fitzgerald, Rebecca C. Morris, Stephen |
author_facet | Swart, Nicholas Maroni, Roberta Muldrew, Beth Sasieni, Peter Fitzgerald, Rebecca C. Morris, Stephen |
author_sort | Swart, Nicholas |
collection | PubMed |
description | BACKGROUND: Esophageal adenocarcinoma has a very poor prognosis unless detected early. The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a precursor of esophageal adenocarcinoma. Randomised controlled trial data from the BEST3 trial has shown that an offer of Cytosponge-TFF3 in the primary care setting in England to individuals on medication for acid reflux increases detection of Barrett esophagus 10-fold over a year compared with standard care. This is an economic evaluation of Cytosponge-TFF3 screening versus usual care using data from the BEST3 trial which took place between 20th March 2017 and 21st March 2019. METHODS: A Markov model with a one-year cycle-length and a lifetime time horizon was created, adapting previous modeling work on Cytosponge screening. The impact of one round of Cytosponge screening was modelled in patients with a median age of 69 years (based on BEST3 trial population). Cost-effectiveness was expressed as an incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were conducted on model parameters. FINDINGS: Per person, one round of Cytosponge-TFF3 screening, including confirmatory endoscopy and treatment, in the intervention arm costed £82 more than usual care and generated an additional 0.015 quality-adjusted life-years (QALYs) at an ICER of £5,500 per QALY gained. Probabilistic sensitivity analysis gave an ICER of £5,405 (95% CI -£6,791 to £17,600). The average QALY gain per person is small because the majority of patients in the model will not develop BE and therefore will have no resulting change in their utility, however the small proportion of patients who are identified with BE dysplasia or cancer derive large benefit. At a willingness-to-pay threshold of £20,000 per QALY, the probability that Cytosponge-TFF3 was cost-effective was over 90%. INTERPRETATION: Using data from a pragmatic randomised trial, one-off Cytosponge-TFF3 screen is cost-effective relative to usual care for patients with gastro-esophageal reflux disease, despite relatively low uptake and an older population in this trial setting than previously modelled. Improving Cytosponge-TFF3 uptake and targeting younger patients is likely to further improve cost-effectiveness. |
format | Online Article Text |
id | pubmed-8225801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-82258012021-06-29 Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data Swart, Nicholas Maroni, Roberta Muldrew, Beth Sasieni, Peter Fitzgerald, Rebecca C. Morris, Stephen EClinicalMedicine Research Paper BACKGROUND: Esophageal adenocarcinoma has a very poor prognosis unless detected early. The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a precursor of esophageal adenocarcinoma. Randomised controlled trial data from the BEST3 trial has shown that an offer of Cytosponge-TFF3 in the primary care setting in England to individuals on medication for acid reflux increases detection of Barrett esophagus 10-fold over a year compared with standard care. This is an economic evaluation of Cytosponge-TFF3 screening versus usual care using data from the BEST3 trial which took place between 20th March 2017 and 21st March 2019. METHODS: A Markov model with a one-year cycle-length and a lifetime time horizon was created, adapting previous modeling work on Cytosponge screening. The impact of one round of Cytosponge screening was modelled in patients with a median age of 69 years (based on BEST3 trial population). Cost-effectiveness was expressed as an incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were conducted on model parameters. FINDINGS: Per person, one round of Cytosponge-TFF3 screening, including confirmatory endoscopy and treatment, in the intervention arm costed £82 more than usual care and generated an additional 0.015 quality-adjusted life-years (QALYs) at an ICER of £5,500 per QALY gained. Probabilistic sensitivity analysis gave an ICER of £5,405 (95% CI -£6,791 to £17,600). The average QALY gain per person is small because the majority of patients in the model will not develop BE and therefore will have no resulting change in their utility, however the small proportion of patients who are identified with BE dysplasia or cancer derive large benefit. At a willingness-to-pay threshold of £20,000 per QALY, the probability that Cytosponge-TFF3 was cost-effective was over 90%. INTERPRETATION: Using data from a pragmatic randomised trial, one-off Cytosponge-TFF3 screen is cost-effective relative to usual care for patients with gastro-esophageal reflux disease, despite relatively low uptake and an older population in this trial setting than previously modelled. Improving Cytosponge-TFF3 uptake and targeting younger patients is likely to further improve cost-effectiveness. Elsevier 2021-06-18 /pmc/articles/PMC8225801/ /pubmed/34195582 http://dx.doi.org/10.1016/j.eclinm.2021.100969 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Paper Swart, Nicholas Maroni, Roberta Muldrew, Beth Sasieni, Peter Fitzgerald, Rebecca C. Morris, Stephen Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data |
title | Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data |
title_full | Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data |
title_fullStr | Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data |
title_full_unstemmed | Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data |
title_short | Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data |
title_sort | economic evaluation of cytosponge®-trefoil factor 3 for barrett esophagus: a cost-utility analysis of randomised controlled trial data |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225801/ https://www.ncbi.nlm.nih.gov/pubmed/34195582 http://dx.doi.org/10.1016/j.eclinm.2021.100969 |
work_keys_str_mv | AT swartnicholas economicevaluationofcytospongetrefoilfactor3forbarrettesophagusacostutilityanalysisofrandomisedcontrolledtrialdata AT maroniroberta economicevaluationofcytospongetrefoilfactor3forbarrettesophagusacostutilityanalysisofrandomisedcontrolledtrialdata AT muldrewbeth economicevaluationofcytospongetrefoilfactor3forbarrettesophagusacostutilityanalysisofrandomisedcontrolledtrialdata AT sasienipeter economicevaluationofcytospongetrefoilfactor3forbarrettesophagusacostutilityanalysisofrandomisedcontrolledtrialdata AT fitzgeraldrebeccac economicevaluationofcytospongetrefoilfactor3forbarrettesophagusacostutilityanalysisofrandomisedcontrolledtrialdata AT morrisstephen economicevaluationofcytospongetrefoilfactor3forbarrettesophagusacostutilityanalysisofrandomisedcontrolledtrialdata AT economicevaluationofcytospongetrefoilfactor3forbarrettesophagusacostutilityanalysisofrandomisedcontrolledtrialdata |